{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Arginine depletion",
      "COVID-19",
      "SARS-CoV-2"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33160064",
  "DateCompleted": {
    "Year": "2021",
    "Month": "01",
    "Day": "18"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "04",
    "Day": "14"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "11",
        "Day": "04"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.ijid.2020.10.100",
      "S1201-9712(20)32304-3"
    ],
    "Journal": {
      "ISSN": "1878-3511",
      "JournalIssue": {
        "Volume": "102",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases",
      "ISOAbbreviation": "Int J Infect Dis"
    },
    "ArticleTitle": "Arginine depletion as a therapeutic approach for patients with COVID-19.",
    "Pagination": {
      "StartPage": "566",
      "EndPage": "570",
      "MedlinePgn": "566-570"
    },
    "Abstract": {
      "AbstractText": [
        "The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a source of significant morbidity and death worldwide, and effective treatments are urgently needed. Clinical trials have focused largely on direct antiviral therapies or on immunomodulation in patients with severe manifestations of COVID-19. One therapeutic approach that remains to be clinically investigated is disruption of the host-virus relationship through amino acid restriction, a strategy used successfully in the setting of cancer treatment. Arginine is an amino acid that has been shown in nonclinical studies to be essential in the life cycle of many viruses. Therefore, arginine depletion may be an effective therapeutic approach against SARS-CoV-2. Several arginine-metabolizing enzymes in clinical development may be a viable approach to induce a low arginine environment to treat COVID-19 and other viral diseases. Herein, we explore the rationale for arginine depletion as a therapeutic approach for COVID-19."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020 The Authors. Published by Elsevier Ltd.. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Columbia University Irving Medical Center, New York, NY, USA."
          }
        ],
        "LastName": "Grimes",
        "ForeName": "Joseph M",
        "Initials": "JM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Columbia University Irving Medical Center, New York, NY, USA."
          }
        ],
        "LastName": "Khan",
        "ForeName": "Shaheer",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Aeglea Biotherapeutics Inc., Austin, TX, USA."
          }
        ],
        "LastName": "Badeaux",
        "ForeName": "Mark",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Aeglea Biotherapeutics Inc., Austin, TX, USA."
          }
        ],
        "LastName": "Rao",
        "ForeName": "Ravi M",
        "Initials": "RM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Aeglea Biotherapeutics Inc., Austin, TX, USA."
          }
        ],
        "LastName": "Rowlinson",
        "ForeName": "Scott W",
        "Initials": "SW"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Columbia University Irving Medical Center, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, New York, NY, USA. Electronic address: rdc2150@cumc.columbia.edu."
          }
        ],
        "LastName": "Carvajal",
        "ForeName": "Richard D",
        "Initials": "RD"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Canada",
    "MedlineTA": "Int J Infect Dis",
    "NlmUniqueID": "9610933",
    "ISSNLinking": "1201-9712"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "94ZLA3W45F",
      "NameOfSubstance": "Arginine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "deficiency"
      ],
      "DescriptorName": "Arginine"
    },
    {
      "QualifierName": [
        "metabolism",
        "therapy",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ]
}